Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.25.3
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine Months Ended September 30, 

($ in thousands)

    

2025

    

2024

    

2025

    

2024

Emrosi

​

$

4,883

​

$

—

​

$

9,748

​

$

—

Qbrexza

​

​

7,361

​

​

7,583

​

​

19,470

​

​

19,435

Accutane

​

​

2,769

​

​

3,996

​

​

9,818

​

​

15,534

Vyne acquisition products (Amzeeq & Zilxi)

​

​

1,311

​

​

2,100

​

​

3,973

​

​

4,703

Other / legacy product revenue

​

​

701

​

​

950

​

​

2,164

​

​

2,842

Revenue – related party

​

 

—

​

 

—

​

 

—

​

 

41

Other revenue

​

​

606

​

​

—

​

​

2,010

​

 

—

Total net revenue

​

$

17,631

​

$

14,629

​

$

47,183

​

$

42,555